Introduction
Beta-blockers, also known as beta-adrenergic blocking agents, are medications that reduce blood pressure by blocking the effects of the hormone epinephrine, also known as adrenaline.1 Beta-blockers prevent epinephrine from binding to beta receptors on cells throughout the body, leading to effects like lowered heart rate and blood pressure.2
Because of these effects, beta-blockers are most commonly used to treat conditions like high blood pressure, irregular heart rhythms (arrhythmias), chest pain (angina), and heart failure.1,3 However, they are also sometimes used to prevent and manage heart attacks, migraines, glaucoma, anxiety, and tremors.1,4
The hormone epinephrine has evolved in humans to produce fight-or-flight responses to threats and stress. It binds to beta receptors in the heart, blood vessels, airways, and elsewhere, causing increased heart rate, constricted blood vessels, and accelerated breathing.5 For patients with heart conditions, blocking some epinephrine effects can relieve strain on the cardiovascular system.
Beta-blocker medications attach to beta receptors and occupy them inertly without activating them, effectively blocking epinephrine from binding to 30-70% of receptors.6,7 This reduces heart rate and dilates blood vessels, lowering blood pressure.8 Beta-blockers also appear to have additional properties beyond receptor blocking that improve heart functioning.9
There are three main types of beta receptors in the human body—beta-1, beta-2, and beta-3.10 Beta-1 receptors are predominantly found in cardiac tissue and make up about 75% of heart beta receptors.2,11 Beta-blockers target beta-1 receptors to produce the greatest cardiovascular effects.
Some beta-blockers are "cardioselective", meaning they specifically target only beta-1 receptors, while others target beta-1 and beta-2 receptors more broadly.10,12 Newer generation beta-blockers also promote vasodilation through nitric oxide release.9 The beta-3 receptor subtype currently plays emerging roles in cardiovascular and metabolic regulation.13
The common side effects of beta-blockers
Beta-blockers work by blocking epinephrine's effects, thereby lowering heart rate and reducing blood pressure.14 These intended therapeutic impacts also lead to common side effects like fatigue, cold extremities, and dizziness. Fatigue and weakness are very common complaints, affecting approximately 18-33% of beta-blocker patients.15
By slowing down heart contractions and lowering systolic blood pressure, less oxygenated blood circulates through the body to supply muscles and tissues.16 Aerobic exercise capacity can be reduced by an average of 7% while on beta blockers.17 However, it is essential to regularly keep taking these medications because abrupt discontinuation can trigger rebound high blood pressure and even worse heart attacks or strokes.18
If fatigue worsens, speaking to a doctor about dosage adjustments or switching medications can help minimise tiredness.19 Scheduling important physical activity after peak beta-blocker effects wear off in the afternoon or evening may also help.20
Another frequent side effect is coldness in the hands and feet due to compromised peripheral circulation.21 Beta-blockers cause vasoconstriction, reducing blood flow volume to the extremities.22 Over months and years of treatment, Reynaud's syndrome can also develop in rare cases, causing digit discolouration and numbness.23
Keeping the whole body warm with socks, gloves, and layers helps minimise temperature regulation effects on the skin. Moving hands and feet periodically also helps maintain blood flow. Dizziness occurs in up to a quarter of patients on beta-blockers when blood pressure dips unpredictably.24
Sudden position changes to standing can trigger a blood pressure drop and brief sensations of light-headedness, wooziness, and loss of balance.25 To reduce risk, move slowly when changing positions and wait a minute before starting to walk. If dizzy spells occur regularly, speaking to a doctor to evaluate medication adjustments or alternatives is important.
Serious side effects of beta-blockers
While they are effective medications, beta blockers can sometimes produce more concerning adverse effects that require medical care. Shortness of breath is one potentially worrisome side effect, as beta blockers can exacerbate asthma and chronic obstructive pulmonary disease (COPD) in susceptible patients.26,27
By blocking epinephrine’s ability to open up bronchial airways, symptoms like wheezing, coughing, and difficulty breathing can occur. If inhalers provide no relief, prompt medical intervention is needed.28 Slow heart rate, also known as bradycardia, affects an estimated 2-17% of patients on beta blockers.28
Excessive suppression of epinephrine’s cardiac stimulation slows the heartbeat too much, causing fatigue, chest pains, and lightheadedness due to oxygen deprivation.29 In serious cases, fainting due to a dangerously low pulse can occur. Seeking prompt medical evaluation for marked fatigue, confusion, or fainting after taking beta blockers is imperative.30
Erectile dysfunction is another unfortunate side effect some male patients experience at rates estimated between 3-16% while on beta blockers.31,32 Blood flow changes can negatively impact sexual performance and enjoyment. Similarly, beta blockers disrupt pancreatic cell receptors involved in insulin release, so they can alter glycemic control in diabetes patients via mechanisms still being elucidated.31
This necessitates more frequent blood sugar testing in diabetic patients on these medications. Thankfully, many modern beta blockers are cardioselective, only blocking beta-1 heart receptors instead of widespread beta cell types, thus producing fewer metabolic effects like blood sugar changes.32
In most cases, the cardiovascular benefits of beta blockers in treating serious conditions like post-heart attack greatly outweigh the temporary side effects experienced.33 However, the above impacts underscore the importance of proactive prevention and symptom monitoring with health providers to maximise therapeutic effects while minimising risks.
Risk factors for beta-blocker side effects
While beta-blockers are largely safe and effective when taken as prescribed, certain patients are at higher risk of experiencing adverse reactions. Those with pre-existing conditions like diabetes, asthma, and chronic obstructive pulmonary disease (COPD) tend to face more numerous and severe side effects from beta-blockers.34,35
For example, beta-blockers can reduce insulin secretion from pancreatic cells, complicate respiratory function, and interfere with medication management of these disorders.35 Using beta blockers cautiously under close medical supervision is vital for those with these conditions. Similarly, patients taking other medications that slow heart rate or affect blood pressure face heightened risk when adding beta-blockers to their regimens.36
Combined effects of mutually reinforced bradycardia, hypotension, and electrocardiographic irregularities can occur. This makes previously safe dosages become excessive or even dangerous.37 Special care must be taken to gradually lower beta blocker dosages and monitor patients' vitals on multiple cardiopulmonary medications.
Finally, abruptly stopping long-term beta-blocker therapy can severely impact patients. Cessation after just two weeks of beta blockers has been associated with a 123% increase in event rates for conditions like acute myocardial infarction and stroke in the subsequent 30 days.38 As a result, safely discontinuing beta blockers requires gradually tapering down dosages for 2-4 weeks under medical guidance.39
This allows the cardiovascular system time to readjust activity levels and prevent life-threatening heart problems. Skipping medication for just 1-2 days without tapering can also trigger “beta-blocker withdrawal syndrome” with hypertension, tremors, and chest pain.40 Following proper cessation protocols ensures patient safety and minimises risks.
Mitigating beta blocker side effects
The adverse effects of beta blockers can often be minimised through proper mitigation strategies. The foremost is taking beta-blocker medications exactly as prescribed by a doctor.14 Skipping doses or abruptly stopping treatment increases side effect risks and reduces cardiovascular benefits.
Similarly, exceeding prescribed dosages in trying to amplify therapeutic impacts can trigger unintended consequences. Carefully following prescription instructions allows beta blockers to work optimally.
Staying hydrated by drinking adequate water also helps circumvent dizziness and headaches.41 Dehydration exacerbates hemodynamic changes induced by beta blockers that can leave patients lightheaded upon standing. Limiting alcohol and caffeinated beverages - which have diuretic and blood pressure-altering effects - assists hydration levels.
Additionally, supplementary medications can successfully counteract certain side effects if they emerge.42 For example, bronchodilators open airways to relieve potential wheezing and asthma symptoms triggered by some beta blockers.34
Similarly, prescription-strength non-steroidal anti-inflammatory drugs (NSAIDs) can provide relief from stubborn headaches as needed if they manifest.43 Phosphodiesterase inhibitors may improve erectile dysfunction as well in some male patients.43
Moreover, promptly reporting any concerning or serious side effects after starting beta blockers is key. Shortness of breath, marked fatigue/lethargy, persistent dizziness, or fainting warrant urgent evaluation to modify treatment.44 Clear communication ensures patient safety and enhanced outcomes. Monitoring for potential drug interactions and contraindications also minimises risks when adding new medications alongside beta blockers.
Summary
In summary, beta-blockers work effectively to control blood pressure, reduce strain on the heart, prevent recurrent heart attacks, and provide additional cardiovascular benefits. However, their therapeutic mechanism of blocking epinephrine can also give rise to numerous side effects like fatigue, cold extremities, impaired breathing, slow heart rate, dizziness, sexual dysfunction, and blood sugar changes. More serious risks manifest when beta-blockers interact poorly with pre-existing medical conditions, other medications, or discontinuation without tapering.
Thankfully, proactively minimising avoidable triggers, properly managing underlying disorders, supplementing to relieve symptoms, staying vigilant about changes, and collaborating closely with healthcare providers can help mitigate adverse impacts in most patients. Given appropriate patient selection, dosing, monitoring, and responsible usage, beta blockers safely improve quality of life and longevity. Their protection for strained hearts continues to outweigh transient side effects. However, understanding and appropriately handling their potential unintended consequences via the strategies outlined empowers patients and enables better care.
References
- www.heart.org [Internet]. [cited 2024 Jan 08]. Types of Blood Pressure Medications. Available from: https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
- Frishman WH, Saunders E. β‐Adrenergic Blockers. J Clin Hypertens. 2011 Aug 8;13(9):649–53.
- Haas SJ, Vos T, Gilbert RE, Krum H. Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003 Nov 1;146(5):848–53.
- Lippmann S. Monoamine oxidase inhibitors. Am Fam Physician. 1986 Jul;34(1):113–9.
- Araujo LP, Maricato JT, Guereschi MG, Takenaka MC, Nascimento VM, de Melo FM, et al. The Sympathetic Nervous System Mitigates CNS Autoimmunity via β2-Adrenergic Receptor Signaling in Immune Cells. Cell Rep. 2019 Sep 17;28(12):3120-3130.e5.
- Frishman WH. beta-Adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15(6):565–76.
- Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013 Jan;3(1):1–58.
- McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46(2):163–97.
- Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67(8):1097–107.
- Woo AYH, Xiao R ping. β-Adrenergic receptor subtype signaling in heart: From bench to bedside. Acta Pharmacol Sin. 2012 Mar;33(3):335–41.
- Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999 Dec;51(4):651–90.
- Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005 Feb;144(3):317–22.
- Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation. 2001 Mar 27;103(12):1649–55.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertens Dallas Tex 1979. 2003 Dec;42(6):1206–52.
- Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol. 2017 Jun 20;69(24):2885–96.
- Foley RN, Herzog CA, Collins AJ, United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int. 2002 Nov;62(5):1784–90.
- de Groote P, Ennezat PV, Mouquet F. Bisoprolol in the treatment of chronic heart failure. Vasc Health Risk Manag. 2007 Aug;3(4):431–9.
- Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2015 Aug;3(8):647–53.
- Choi KH, Lee GY, Choi JO, Jeon ES, Lee HY, Lee SE, et al. The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Korean J Intern Med. 2019 Sep;34(5):1030–9.
- Talbert RL. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev. 2004 Apr;9(2):131–7.
- Ohlsson O, Lindell SE. The effects of pindolol and prazosin on hand blood flow in patients with cold extremities and on treatment with beta-blockers. Acta Med Scand. 1981;210(3):217–9.
- Chung CM, Lin MS, Chang ST, Wang PC, Yang TY, Lin YS. Cardioselective Versus Nonselective β-Blockers After Myocardial Infarction in Adults With Chronic Obstructive Pulmonary Disease. Mayo Clin Proc. 2022 Mar;97(3):531–46.
- Khouri C, Blaise S, Carpentier P, Villier C, Cracowski J, Roustit M. Drug‐induced Raynaud’s phenomenon: beyond β‐adrenoceptor blockers. Br J Clin Pharmacol. 2016 Jul;82(1):6–16.
- Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet Lond Engl. 2000 Dec 9;356(9246):1955–64.
- Mol A, Bui Hoang PTS, Sharmin S, Reijnierse EM, van Wezel RJA, Meskers CGM, et al. Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2019 May;20(5):589-597.e5.
- Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010 May 24;170(10):880–7.
- Salpeter SR, Ormiston TM, Salpeter EE, Wood‐Baker R. Cardioselective beta‐blockers for reversible airway disease. Cochrane Database Syst Rev. 2002 Oct 21;2002(4):CD002992.
- Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013 Jul 13;13:52.
- Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014 May 13;63(18):1879–89.
- DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757–65.
- Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clin Pharm. 1985 Apr;19(4):246–51.
- Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996 Apr;14(4):489–94.
- Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308(13):1340–9.
- Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014 Apr;145(4):779–86.
- Kubota Y, Tay WT, Teng TK, Asai K, Noda T, Kusano K, et al. Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease. ESC Heart Fail. 2021 Jun 29;8(5):3791–9.
- Frishman WH. Carvedilol. N Engl J Med. 1998 Dec 10;339(24):1759–65.
- Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J. 1979 May;97(5):663–70.
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023 Jul 13;389(2):107–17.
- James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507–20.
- Tanabe T, Rozycki HJ, Kanoh S, Rubin BK. Cardiac asthma: new insights into an old disease. Expert Rev Respir Med. 2012 Dec;6(6):705–14.
- Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens. 2008 Mar;26(3):381–91.
- Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002 Jul 17;288(3):351–7.
- Shaik MM, Gan SH. Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine. BioMed Res Int. 2015;2015:469529.
- Viigimaa M, Vlachopoulos C, Lazaridis A, Doumas M. Management of erectile dysfunction in hypertension: Tips and tricks. World J Cardiol. 2014 Sep 26;6(9):908–15.